Evaluation of the Effectiveness of the Belatacept (Nulojix) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries

Trial Profile

Evaluation of the Effectiveness of the Belatacept (Nulojix) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to completed.
    • 13 Apr 2017 Planned End Date changed from 1 Jan 2017 to 30 Jun 2017.
    • 13 Apr 2017 Planned primary completion date changed from 1 Oct 2016 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top